Search clinical trials for: Vaccine immunogenicity

Total 10545 results

Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe

Meningococcal Infections

Czechia, Finland, Italy, Poland, Romania, Spain, Sweden
Centers for Disease Control and Prevention
Ministry of Health, Thailand

Completed

Immunogenicity of Influenza Vaccines in HIV-infected Persons in Thailand

Influenza

Thailand
BioNTech SE
Pfizer

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza

COVID-19 | Influenza, Human

United States
National Institute of Allergy and Infectious Diseases...
Gritstone bio, Inc.

Completed

Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults

COVID-19

United States
National Institute of Allergy and Infectious Diseases...

Completed

Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects

Rabies | Rabies Immunisation

United States
Teva takeda

Active, not recruiting

Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children (TIDES)

Healthy Volunteers

Thailand, Brazil, Colombia, Dominican Republic, Nicaragua, Panama, Philippines, Sri Lanka
Sinovac Research and Development Co., Ltd.

Completed

Immunogenicity and Safety of Booster Immunization of COVID-19 Vaccine (Vero Cell), Inactivated (Omicron Variant) in Healthy People Aged 18 Years and Above

COVID-19

China
GlaxoSmithKline

Active, not recruiting

Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System in Medically Stable Adults

Influenza, Human

United States
Centers for Disease Control and Prevention
San Lucas Hospital, Ponce, Puerto Rico

Completed

Comparison of Immune Response Using 2 Vaccination Schedules Using Inactivated Polio Vaccine

Poliomyelitis

Puerto Rico
Duke University
Washington University School of Medicine; University of Pittsburgh; Centers for... and other collaborators

Completed

Comparative Immunogenicity of Concomitant vs Sequential mRNA COVID-19 and Influenza Vaccinations

COVID-19 | Influenza

United States
National Institute of Allergy and Infectious Diseases...
Ina-Respond; Institut National de Recherche Biomédicale. Kinshasa, République... and other collaborators

Active, not recruiting

International Study on COVID-19 Vaccine to Assess Immunogenicity, Reactogenicity and Efficacy (InVITE) (InVITE)

COVID-19

Congo, The Democratic Republic of the, Guinea, Indonesia, Liberia, Mali, Mexico, Mongolia
Merck Sharp & Dohme LLC

Completed

Safety and Immunogenicity of V116 in Vaccine-naïve Japanese Older Adults (V116-009, STRIDE-9)

Pneumococcal Disease

Japan
Novavax

Completed

A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. (COVID-19)

COVID-19

United States
Centers for Disease Control and Prevention
Mayo Clinic; Baylor College of Medicine; University of Alabama at Birmingham; Emory... and other collaborators

Completed

Anthrax Vaccine Clinical Trial to Assess Dose Reduction and Route Change (AVRP)

Healthy

United States
Pfizer

Active, not recruiting

A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan

Pneumococcal Disease

Taiwan, India
Minervax ApS
Iqvia Pty Ltd

Completed

Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Doses of GBS Vaccine in Elderly Participants

Group B Streptococcal Infections

Belgium
University of Peshawar
Hayatabad Medical Complex

Completed

Safety and Immunogenicity of Purified Verocell Rabies Vaccine PVRV Administered Intramuscularly and Intradermally

Rabies

Pakistan
Seqirus

Active, not recruiting

A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Quadrivalent Influenza Vaccine Compared to a Non-adjuvanted Quadrivalent Influenza Vaccine in Adults ≥65 Years of Age

Influenza, Human

Turkey, Belgium, Bulgaria, Czechia, Finland, Georgia, Italy, Korea, Republic of, Lithuania, Netherlands, Poland, Romania, Spain, Taiwan
Health Institutes of Turkey

Completed

Efficacy, Immunogenicity, and Safety of TURKOVAC Vaccine Versus the CoronaVac Vaccine Against COVID-19 in Healthy Adolescent

COVID-19 | Sars-CoV-2 Infection

Turkey
University of Witwatersrand, South Africa

Completed

Persistence of Immunogenicity Following Reduced PCV Dosing Schedules in South African Children (PCV1+1_FU)

Pneumonia | Meningitis

South Africa
Seqirus

Active, not recruiting

Safety, Reactogenicity, and Immunogenicity Study of a Self-Amplifying mRNA Influenza Vaccine in Healthy Adults

Influenza, Human

Australia
Sinovac Biotech Co., Ltd
Pontificia Universidad Catolica de Chile; Sinovac Biotech Co., Ltd

Completed

Immunogenicity and Safety Study of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent

Seasonal Influenza

Philippines, Chile
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)

Pneumococcal Disease

United States, Austria, Canada, Denmark, Finland, Israel, Poland, Spain
Health Institutes of Turkey

Completed

Observational National Vaccine Study

COVID-19 Infection

Turkey
PharmaJet, Inc.
National Cancer Institute (NCI); National Institutes of Health (NIH)

Withdrawn

Safety and Immunogenicity of HPV Vaccine Administered Intradermally and Intramuscularly Via Needle-Free Injection System

Vaccine Reaction

Indonesia
Novartis Vaccines

Completed

Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects

Influenza

Finland, United States, Poland
Pfizer

Completed

Trial to Evaluate the Safety, Tolerability, and Immunogenicity of A Multivalent Group B Streptococcus Vaccine When Administered Concomitantly With Tdap in Healthy Nonpregnant Women

Group B Streptococcus Infections

United States
Merck Sharp & Dohme LLC

Completed

Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066)

Papillomavirus Infections

Japan
PharmaJet, Inc.
United States Department of Defense

Active, not recruiting

Safety, Reactogenicity and Immunogenicity of a Venezuelan Equine Encephalitis DNA Vaccine Candidate Administered by Jet Injection

Vaccine Reaction

United States
Dynavax Technologies Corporation
United States Department of Defense

Completed

Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age

Vaccine-Preventable Diseases | Plague | Plague, Pneumonic

United States
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)

Pneumococcal Infections

United States
Vaxart

Completed

Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines (VXA-NVV-105)

Norovirus Infections

United States
GlaxoSmithKline

Active, not recruiting

A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above (RSV OA=ADJ-023)

Respiratory Syncytial Virus Infections

Spain, Japan, Italy, United States, Australia, Canada, Korea, Republic of, Germany
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immunogenicity of EnvSeq-1 and CH505 M5 gp120 Envs Adjuvanted With GLA-SE in Healthy, HIV-Uninfected Adults

HIV Infections

United States
GlaxoSmithKline

Completed

A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above

Respiratory Syncytial Virus Infections

Argentina, United States, Germany, Spain, Poland, Canada, Japan, Netherlands
GlaxoSmithKline

Completed

Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age

Malaria

Ghana, Kenya
National Institute of Allergy and Infectious Diseases...

Completed

Safety, Tolerability, and Immunogenicity Study of Sm-p80 + GLA-SE (SchistoShield(R)) Vaccine in Healthy Adults

Schistosomiasis

United States
Merck Sharp & Dohme LLC

Completed

Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003)

Dengue Virus | Dengue Disease

United States, Australia, Canada, Finland, Germany, Israel, Taiwan
Hipra Scientific, S.L.U

Active, not recruiting

Safety and Immunogenicity of a Booster Vaccination With an Adapted Vaccine

SARS-CoV2 Infection

Spain
VBI Vaccines Inc.

Completed

Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a

Covid19

Canada
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age

Respiratory Syncytial Virus (RSV)

United States
Seqirus
Biomedical Advanced Research and Development Authority

Active, not recruiting

Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults

Infections | Virus Diseases | Respiratory Tract Infections | Influenza, Human | Infection Viral

United States
University of Oxford
Malaria Research and Training Center, Bamako, Mali

Active, not recruiting

Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines

Malaria

Mali, United Kingdom
University of Washington

Active, not recruiting

Immunogenicity of Fractional Dose of the HPV Vaccines

HPV Infection | HPV Vaccine

United States
Novavax

Completed

A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine (COVID-19)

COVID-19 | Influenza

Australia, New Zealand
National Institute of Allergy and Infectious Diseases...

Terminated

Assess the Safety and Immunogenicity of One or Two Doses of Sing2016 M2SR H3N2 Influenza Vaccine

H3N2 Influenza

United States
University of Wisconsin, Madison
Novavax

Suspended

Additional Recombinant COVID-19 Humoral and Cell-Mediated Immunogenicity in Immunosuppressed Populations

COVID-19 | Immunosuppression

United States
Janssen Vaccines & Prevention B.V.

Completed

A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults (IPCAVD-012)

Healthy

United States, Rwanda, Kenya
University of Oxford

Enrolling by invitation

Immunogenicity of COVID-19 Vaccines in Tuberculosis Patients (CVTB)

Tuberculosis | Covid-19 Pandemics

Thailand
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older

Influenza Immunization

Australia, United States, Puerto Rico

3

Subscribe